About CorneaGen
CorneaGen is a Healthcare company based in Seattle (United States) founded in 2017. It operates as a therapeutic devices for corneal transplants are developed by CorneaGen. CorneaGen has raised $42 million across 3 funding rounds from investors including Petrichor and Flying L Partners. The company has 205 employees. CorneaGen has completed 1 acquisition, including KeraLink International. Its chief executive is Monty Montoya. CorneaGen offers products and services including CTAK, EndoSerter-PL, VisionGraft, and Geuder Pre-Loaded Glass Cannula. Its focus areas include Life Sciences, Ophthalmology, Medical Devices and Therapy. Its competitors include Cellusion, EyeGate, CorNeat Vision, Avedro and EyeYon and 3 more; 6 of its 8 listed competitors have raised funding.
Company details
CorneaGen was founded in 2017 and is based in Seattle, United States. Operations center on the development of therapeutic devices within the ophthalmology sector, specifically for corneal transplant procedures. Key products include Ampho B, Pre-Loaded Cannula, Cannula, Donor Punch, EndoSerter, and Recipient Trephine. These devices support surgical processes for corneal care and are targeted at medical professionals in the field.
- Headquarters Seattle, United States
- Employees 205
- SectorsHealthcare
- Email••••••••
- Phone•••• ••••
- Website corneagen.com
- Social LinkedIn X Facebook
- Total Equity Funding$42M (USD)
in 3 rounds
- Latest Funding Round$25M (USD), Debt – Conventional
Oct 2019
- InvestorsPetrichor
& 1 more
- Employee Count205
- Investments & Acquisitions
Products & Services of CorneaGen
CorneaGen offers a comprehensive portfolio of products and services, including CTAK, EndoSerter-PL, VisionGraft, and Geuder Pre-Loaded Glass Cannula.
Provides laser-cut tissue inlays for enhanced vision in keratoplasty.
Pre-loaded tool for DSEK procedures to improve surgical outcomes.
Offers ready corneal grafts for ocular surgeries to restore sight.
Facilitates DMEK surgery with pre-loaded delivery for precision.
Funding Insights of CorneaGen
CorneaGen has successfully raised a total of $42M across 3 strategic funding rounds. The most recent funding activity was a Debt – Conventional round of $25 million completed in October 2019. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $42M
- Total Rounds 3
- Last Round Debt – Conventional — $25M
- First Round $5M
(Apr 2018)
- Investors Count 2
All 3 funding rounds of CorneaGen with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Oct 2019 | $25M | Debt – Conventional | – | – | |
| Feb 2019 | $37M | Series B | – | Flying L Partners | |
| Apr 2018 | $5M | Series A | – | – | – |
2 investors in total: 2 institutional.
Investors in CorneaGen
CorneaGen has secured backing from 2 investors, including venture fund investors. Prominent investors backing the company include Petrichor and Flying L Partners.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Petrichor is engaged in supporting healthcare innovation through investments. | 2018 | petrichorcap.com | New York, USA | |
Flying L Partners is focused on ophthalmic sector investments. | – | flyinglpartners.com | - |
Investor details for CorneaGen
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of CorneaGen
68 people are tracked at CorneaGen (24 in leadership, 12 in board & advisors, 32 in team); the tracked headcount is 205.
| Name | Role | Group |
|---|---|---|
Monty Montoya | CEO & President | Leadership |
Tom Buckley | VP of Ocular Operations | Leadership |
Chris Lanier | VP of Distribution Services | Leadership |
John Guckes | Chief Executive Advisor | Leadership |
Tom Miller | VP of Quality Assurance | Leadership |
Kyle Crawford | VP of Technology Services | Leadership |
Heather Smith | VP, Human Resources | Leadership |
Bernie Iliakis | President & CEO | Leadership |
Annie Thompson | Chief Financial Officer | Leadership |
Jerry Barker | VP Commercial Operations | Surgeon Education, Cornea Tissue Procedures, Biologics, Inventions | Leadership |
Anneli Bojstad | VP Of Marketing And Communications | Leadership |
Heather S. | Vice President Human Resources | Leadership |
Ravi Sundaram | Director Of Business Applications | Leadership |
Christina Cooper | Quality Assurance Director | Leadership |
Andrew Beal | Director Information Technology Infrastructure | Leadership |
Nick Hunt | Director Of Marketing | Leadership |
Julie Todd | Director Of Operations | Leadership |
Angela Clausen | Director Of Partner Relations | Leadership |
Amanda Larussa | Director Of Technical Product Management | Leadership |
Lauren Buckley | Senior Director Of Operations | Leadership |
48 more people are available in the full profile.
Complete people profiles for CorneaGen
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Investments & Acquisitions by CorneaGen
CorneaGen has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include KeraLink International.
| Company Name | Description | Domain | Location | Founded | Acquired | Amount |
|---|---|---|---|---|---|---|
Foundation focused on developing affordable corneal blindness treatment | keralink.org | Baltimore, United States | 1962 | Feb 2019 | •••• |
Complete acquisition details for CorneaGen
Acquired stakes, deal sources and the complete acquisition history require an active premium plan.
- Acquired stakes
- Deal sources
- Complete history
- Exports
Verified entity values are shown only after access is granted.
Timeline of CorneaGen
4 dated milestones of CorneaGen across 2 years, from founding to its latest funding, stage changes and deals.
- Founded CorneaGen is founded.
- Funding First funding round of $5.0M.
- Acquisition Acquires KeraLink International.
- Funding Latest funding round, Debt – Conventional, of $25.0M.
Competitors of CorneaGen
CorneaGen has 8 listed competitors in our database, 6 of them funded. They include Cellusion, EyeGate, CorNeat Vision, Avedro and EyeYon, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| cellusion.jp | 2015 | Minato, Japan | $29.71M | – | iPS cell-based technology for corneal endothelium regeneration is developed. | |
| eyegatepharma.com | 1998 | Waltham, United States | $44.47M | 12 | Therapeutics and drug delivery systems for eye diseases are developed. | |
| corneat.com | 2015 | – | $4M | – | Nanotechnology-based artificial corneal implants are developed for ophthalmic use. | |
| avedro.com | 2007 | Waltham, United States | $210.76M | 113 | Corneal collagen cross-linking technology is developed for ophthalmic applications. | |
| eye-yon.com | 2011 | Ness Ziona, Israel | $35.1M | – | Ophthalmic devices for corneal edema treatment are developed. | |
| nueyne.com | 2017 | Seoul, South Korea | – | – | Medical devices using electrical stimulation for health conditions are developed. | |
| recornea.com | 2019 | Udine, Italy | $161,997 | – | Provider of corneal implants devices for the treatment of eye diseases | |
| biolatticetech.com | 2017 | Philadelphia, United States | – | – | Solutions for tissue repair and restoration are developed. |
Detailed competitors of CorneaGen
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of CorneaGen
The website of CorneaGen (corneagen.com) receives about 4.4K visits a month.
- Monthly visits4.4K
▼ 2.9% vs previous month
Top companies in Ophthalmology
10 companies that operate in the same segment as CorneaGen (Ophthalmology), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Developer of a wide range of eye care products | 1945 | Fort Worth, Texas, United States | USD 171.61 M | USD 9.64 B | 25,600 | |
Genetic medicines are developed by 4DMT for transformative therapies. | 2013 | Emeryville, California, United States | USD 186.59 M | USD 85.21 M | 227 | |
Developer of antibodies to treat complement-mediated neurodegenerative diseases | 2011 | San Francisco, California, United States | USD 256 M | – | 100 | |
Ophthalmic pharmaceuticals for diabetic macular edema are developed and commercialized. | 2003 | Alpharetta, Georgia, United States | USD 66.8 M | USD 80.75 M | 79 | |
AI-powered portable solutions for ophthalmic screening and diagnosis are developed. | 2009 | Bengaluru, Karnataka, India | USD 25.01 M | USD 4.85 M | 135 | |
Gene therapies for ocular and neurodegenerative diseases are developed. | 2015 | New York, New York, United States | – | USD 81.39 M | 381 | |
Small molecule therapeutics for ophthalmic disorders are developed. | 1987 | Watertown, United States | – | USD 31.37 M | 165 | |
Therapies for metabolic and orphan diseases are developed by Rezolute. | 2012 | Denver, Colorado, United States | – | – | 59 | |
Manufacturer of portable digital eye imaging devices and cloud-based healthcare platforms | 2010 | Bengaluru, Karnataka, India | USD 18.12 M | USD 4.78 M | 145 | |
Therapeutics for retinal diseases are developed by the company. | 2009 | Palo Alto, California, United States | USD 35.84 M | – | 109 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Corneagen
Complete news archive for CorneaGen
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about CorneaGen
CorneaGen was founded in 2017 and raised its 1st funding round 1 year after it was founded.
CorneaGen is headquartered in Seattle, United States. It is registered at Seattle, Washington, United States.
Monty Montoya is the current CEO of CorneaGen.
CorneaGen is a funded company, having raised a total of $42M across 3 funding rounds to date. The company's 1st funding round was a Series A of $5M, raised on Apr 2018.
CorneaGen has 205 employees.
CorneaGen was founded in 2017 and is based in Seattle, United States. Operations center on the development of therapeutic devices within the ophthalmology sector, specifically for corneal transplant procedures. Key products include Ampho B, Pre-Loaded Cannula, Cannula, Donor Punch, EndoSerter, and Recipient Trephine. These devices support surgical processes for corneal care and are targeted at medical professionals in the field.
CorneaGen offers CTAK, EndoSerter-PL, VisionGraft, and Geuder Pre-Loaded Glass Cannula.
CorneaGen has made 1 acquisition, including KeraLink International.
CorneaGen has 2 investors. Key investors include Petrichor, and Flying L Partners.